Medroxyprogesterone: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ===Non-pregnant vaginal bleeding=== *'''20 mg PO TID for 7 days'''<ref name="ACOG" /> **76% success, median time 3 days *Alternative, not officially endorsed by ACOG: 150mg IM x 1 then 20 mg PO TID x 3 days **In a trial of 48 patients all had cessation in 5 days.<ref name="highdose">Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient...") |
(Fix cite error: add ACOG citation content to empty named ref) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Non-pregnant vaginal bleeding]]=== | ===[[Non-pregnant vaginal bleeding]]=== | ||
*'''20 mg PO TID for 7 days'''<ref name="ACOG" /> | *'''20 mg PO TID for 7 days'''<ref name="ACOG">American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 557: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. Obstet Gynecol. 2013;121(4):891-896. doi:10.1097/01.AOG.0000428646.67925.9a</ref> | ||
**76% success, median time 3 days | **76% success, median time 3 days | ||
*Alternative, not officially endorsed by ACOG: 150mg IM x 1 then 20 mg PO TID x 3 days | *Alternative, not officially endorsed by ACOG: 150mg IM x 1 then 20 mg PO TID x 3 days | ||
**In a trial of 48 patients all had cessation in 5 days.<ref name="highdose">Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013. 208(6):499.e1-e5.</ref> | **In a trial of 48 patients all had cessation in 5 days.<ref name="highdose">Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013. 208(6):499.e1-e5.</ref> | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 37: | Line 32: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
* History of [[VTE]] | |||
* History of arterial [[thromboembolic events]] | |||
* History of breast cancer | |||
* Liver disease | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
Latest revision as of 01:01, 21 March 2026
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
Non-pregnant vaginal bleeding
- 20 mg PO TID for 7 days[1]
- 76% success, median time 3 days
- Alternative, not officially endorsed by ACOG: 150mg IM x 1 then 20 mg PO TID x 3 days
- In a trial of 48 patients all had cessation in 5 days.[2]
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- History of VTE
- History of arterial thromboembolic events
- History of breast cancer
- Liver disease
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 557: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. Obstet Gynecol. 2013;121(4):891-896. doi:10.1097/01.AOG.0000428646.67925.9a
- ↑ Ammerman SR, Nelson AL. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013. 208(6):499.e1-e5.